Assessed for eligibility = 241

Excluded = 119

* Not meeting inclusion criteria = 37
* Declined participation = 82

Individuals declined participation in randomised trial but consented to observational study = 26. (Participant characteristics described in table S7).

Randomised = 122\*

Allocated to sildenafil = 63

Allocated to placebo = 59

Included in analysis = 63

Missing primary outcome data = 2 (no ultrasound after intervention commenced – fetal death or delivery occurred within 48 hours)

Lost to follow-up = 0

Early discontinuation of intervention =5

* Participant request = 3
* Safety concern at investigator request = 2

Lost to follow-up = 0

Early discontinuation of intervention =4

* Participant request = 4
* Safety concern at investigator request =0

Included in analysis = 59

Missing primary outcome data = 2 (no ultrasound after intervention commenced – fetal death or delivery occurred within 48 hours)

**Figure 1.** CONSORT Diagram. Screening, Enrolment, Randomisation and Follow-up

\* One participant was recruited at 28+0 – 29+6 weeks gestation with an estimated fetal weight <700g, all other participants had a fetal abdominal circumference ≤3rd percentile at 22+0 – 27+6 weeks gestation.